In Q2 the firm filed for FDA Emergency Use Authorization for its saliva-based Advanta Sx SARS-CoV-2 RT-PCR assay as it continued its pivot to COVID-19 testing.
Although its research test volume decreased significantly because of the COVID-19 pandemic, the company saw revenue growth across both clinical testing and development services.
Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.
